Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Biliary Tract Neoplasms | 6 | 2023 | 177 | 0.810 |
Why?
|
Carcinoma, Hepatocellular | 13 | 2023 | 2185 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 11410 | 0.780 |
Why?
|
Liver Neoplasms | 15 | 2023 | 4216 | 0.730 |
Why?
|
Organoplatinum Compounds | 7 | 2019 | 409 | 0.710 |
Why?
|
Fluorouracil | 6 | 2019 | 1609 | 0.640 |
Why?
|
Cholangiocarcinoma | 5 | 2023 | 506 | 0.630 |
Why?
|
Bile Duct Neoplasms | 5 | 2023 | 564 | 0.630 |
Why?
|
Pancreatic Neoplasms | 10 | 2024 | 5213 | 0.620 |
Why?
|
Camptothecin | 3 | 2017 | 570 | 0.580 |
Why?
|
Stomach Neoplasms | 4 | 2020 | 1318 | 0.550 |
Why?
|
Gallbladder Neoplasms | 3 | 2023 | 182 | 0.420 |
Why?
|
Adenocarcinoma | 6 | 2023 | 6318 | 0.400 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2023 | 186 | 0.390 |
Why?
|
Antineoplastic Agents | 13 | 2023 | 13635 | 0.380 |
Why?
|
Colorectal Neoplasms | 8 | 2023 | 6726 | 0.370 |
Why?
|
Antibodies, Monoclonal | 12 | 2023 | 9259 | 0.340 |
Why?
|
Bile Ducts, Intrahepatic | 3 | 2023 | 294 | 0.280 |
Why?
|
Dermatofibrosarcoma | 1 | 2006 | 62 | 0.270 |
Why?
|
Gastrointestinal Neoplasms | 4 | 2023 | 981 | 0.270 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2020 | 435 | 0.250 |
Why?
|
Deoxycytidine | 6 | 2023 | 825 | 0.240 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.230 |
Why?
|
Protein Kinase Inhibitors | 6 | 2023 | 5502 | 0.220 |
Why?
|
Phenylurea Compounds | 3 | 2021 | 524 | 0.220 |
Why?
|
Esophageal Neoplasms | 3 | 2020 | 1575 | 0.220 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2024 | 1607 | 0.220 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 86 | 0.210 |
Why?
|
Leucovorin | 3 | 2019 | 618 | 0.200 |
Why?
|
Triazoles | 2 | 2020 | 906 | 0.200 |
Why?
|
Biliary Tract | 1 | 2022 | 134 | 0.200 |
Why?
|
Sirolimus | 4 | 2013 | 1559 | 0.190 |
Why?
|
Carcinoid Tumor | 2 | 2013 | 235 | 0.180 |
Why?
|
Neutropenia | 2 | 2023 | 888 | 0.180 |
Why?
|
Anus Neoplasms | 1 | 2024 | 329 | 0.180 |
Why?
|
Cancer Care Facilities | 2 | 2014 | 401 | 0.180 |
Why?
|
Gallstones | 1 | 2022 | 286 | 0.180 |
Why?
|
ras Proteins | 3 | 2014 | 1062 | 0.170 |
Why?
|
Albumins | 2 | 2023 | 563 | 0.170 |
Why?
|
Rod Cell Outer Segment | 3 | 2001 | 59 | 0.170 |
Why?
|
Pigment Epithelium of Eye | 3 | 2001 | 231 | 0.160 |
Why?
|
Paclitaxel | 3 | 2023 | 1701 | 0.150 |
Why?
|
Esophagogastric Junction | 1 | 2019 | 312 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2455 | 0.140 |
Why?
|
Aged | 30 | 2023 | 162698 | 0.140 |
Why?
|
Neuroendocrine Tumors | 2 | 2013 | 593 | 0.140 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1675 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2014 | 3453 | 0.140 |
Why?
|
Middle Aged | 30 | 2021 | 212863 | 0.130 |
Why?
|
Proto-Oncogene Proteins | 4 | 2014 | 4555 | 0.130 |
Why?
|
Neoplasm Metastasis | 5 | 2017 | 4832 | 0.130 |
Why?
|
Cholecalciferol | 1 | 2019 | 534 | 0.120 |
Why?
|
Anilides | 1 | 2017 | 405 | 0.120 |
Why?
|
Pyridines | 2 | 2017 | 2810 | 0.120 |
Why?
|
Aged, 80 and over | 15 | 2021 | 57650 | 0.120 |
Why?
|
Exercise Therapy | 1 | 2020 | 897 | 0.110 |
Why?
|
Metformin | 1 | 2020 | 827 | 0.110 |
Why?
|
Glypicans | 1 | 2013 | 33 | 0.110 |
Why?
|
Humans | 50 | 2024 | 739398 | 0.110 |
Why?
|
Male | 33 | 2023 | 349022 | 0.110 |
Why?
|
Female | 34 | 2023 | 378853 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1674 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1585 | 0.100 |
Why?
|
Indoles | 2 | 2011 | 1832 | 0.100 |
Why?
|
beta Karyopherins | 1 | 2011 | 47 | 0.100 |
Why?
|
Disease-Free Survival | 7 | 2017 | 6871 | 0.100 |
Why?
|
Databases, Factual | 2 | 2018 | 7690 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2012 | 773 | 0.090 |
Why?
|
Vitamins | 1 | 2019 | 1602 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2014 | 664 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2037 | 0.090 |
Why?
|
Adult | 22 | 2021 | 213394 | 0.090 |
Why?
|
Quinazolines | 2 | 2013 | 1356 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4014 | 0.080 |
Why?
|
Quinolines | 1 | 2013 | 721 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2021 | 2737 | 0.080 |
Why?
|
Tubulin | 1 | 2011 | 696 | 0.080 |
Why?
|
Withholding Treatment | 1 | 2011 | 596 | 0.070 |
Why?
|
United States | 5 | 2020 | 69573 | 0.070 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5632 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1659 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2020 | 5148 | 0.070 |
Why?
|
Photoreceptor Cells | 1 | 1987 | 254 | 0.070 |
Why?
|
Phagocytosis | 3 | 2001 | 1539 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2019 | 3279 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2024 | 76631 | 0.070 |
Why?
|
Decision Making | 2 | 2017 | 3854 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1366 | 0.060 |
Why?
|
Recombinant Fusion Proteins | 1 | 2014 | 3770 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 545 | 0.060 |
Why?
|
Retinal Degeneration | 2 | 2001 | 422 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2102 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8605 | 0.060 |
Why?
|
Cohort Studies | 4 | 2023 | 40389 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5446 | 0.060 |
Why?
|
Electronic Health Records | 2 | 2018 | 4426 | 0.060 |
Why?
|
Data Collection | 1 | 2013 | 3341 | 0.060 |
Why?
|
Estradiol | 1 | 2010 | 2021 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2018 | 551 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1142 | 0.050 |
Why?
|
Neoplasm Staging | 5 | 2019 | 10961 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2014 | 6516 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2023 | 315 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1637 | 0.050 |
Why?
|
Chemokine CXCL12 | 2 | 2017 | 462 | 0.050 |
Why?
|
Treatment Outcome | 10 | 2021 | 62693 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2026 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10534 | 0.050 |
Why?
|
Pyrimidinones | 1 | 2023 | 371 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 643 | 0.050 |
Why?
|
Survival Rate | 3 | 2020 | 12761 | 0.050 |
Why?
|
Maximum Tolerated Dose | 2 | 2013 | 888 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 648 | 0.040 |
Why?
|
Gadolinium DTPA | 1 | 2023 | 836 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2687 | 0.040 |
Why?
|
Colonic Neoplasms | 1 | 2011 | 2530 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 415 | 0.040 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2897 | 0.040 |
Why?
|
Edema | 1 | 2023 | 791 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2022 | 38942 | 0.040 |
Why?
|
Pyridones | 1 | 2023 | 707 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1583 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2023 | 603 | 0.040 |
Why?
|
Hyperbilirubinemia | 1 | 2017 | 73 | 0.040 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2017 | 141 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1822 | 0.040 |
Why?
|
Epistaxis | 1 | 2017 | 112 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1820 | 0.030 |
Why?
|
Intestinal Fistula | 1 | 2017 | 140 | 0.030 |
Why?
|
Angiopoietin-2 | 1 | 2017 | 167 | 0.030 |
Why?
|
Carbachol | 1 | 1996 | 226 | 0.030 |
Why?
|
Pancreas | 1 | 2022 | 1678 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 28901 | 0.030 |
Why?
|
NF-kappa B | 1 | 2024 | 2502 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2019 | 11985 | 0.030 |
Why?
|
Intestinal Perforation | 1 | 2017 | 252 | 0.030 |
Why?
|
Mutation | 2 | 2023 | 29658 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2024 | 2517 | 0.030 |
Why?
|
Signal Transduction | 3 | 2013 | 23355 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1617 | 0.030 |
Why?
|
Prospective Studies | 3 | 2024 | 53037 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2017 | 3194 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6361 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6610 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 20676 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2017 | 3504 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 173 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2015 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2017 | 578 | 0.030 |
Why?
|
Administration, Oral | 2 | 2011 | 3909 | 0.030 |
Why?
|
Hydroxyestrones | 1 | 2010 | 18 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2217 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3508 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 390 | 0.020 |
Why?
|
Somatostatin | 1 | 2012 | 460 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12328 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10945 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4424 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6478 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7275 | 0.020 |
Why?
|
Rats, Mutant Strains | 2 | 2001 | 70 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5293 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2133 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 135 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3752 | 0.020 |
Why?
|
Patient Dropouts | 1 | 2010 | 419 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 2861 | 0.020 |
Why?
|
Survival Analysis | 2 | 2011 | 10247 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2023 | 14740 | 0.020 |
Why?
|
Cycloheximide | 1 | 1987 | 347 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1407 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 9812 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5652 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1650 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1987 | 2198 | 0.020 |
Why?
|
Proteins | 1 | 2001 | 6082 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1244 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3197 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12237 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 21863 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 2986 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 3562 | 0.020 |
Why?
|
Tumor Burden | 1 | 2010 | 1904 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6370 | 0.020 |
Why?
|
Piperidines | 1 | 2012 | 1597 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10455 | 0.010 |
Why?
|
Rats | 3 | 2001 | 24270 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12640 | 0.010 |
Why?
|
Young Adult | 2 | 2021 | 56255 | 0.010 |
Why?
|
Temperature | 1 | 1987 | 2202 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 2001 | 387 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 35326 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3694 | 0.010 |
Why?
|
Kinetics | 1 | 1987 | 6475 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2001 | 1583 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2012 | 4143 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2933 | 0.010 |
Why?
|
Animals | 4 | 2023 | 168368 | 0.010 |
Why?
|
Palliative Care | 1 | 2014 | 3461 | 0.010 |
Why?
|
Liver | 1 | 2014 | 7449 | 0.010 |
Why?
|
Time Factors | 2 | 2011 | 40050 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2009 | 2261 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1987 | 2864 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1996 | 19220 | 0.010 |
Why?
|
Hypertension | 1 | 2017 | 8431 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8400 | 0.010 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 1996 | 114 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81002 | 0.010 |
Why?
|
Lithium Chloride | 1 | 1996 | 87 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3566 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 71974 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13237 | 0.010 |
Why?
|
Hospitalization | 1 | 2014 | 10208 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4743 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2001 | 1662 | 0.010 |
Why?
|
Blotting, Western | 1 | 2001 | 5181 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 85405 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20055 | 0.010 |
Why?
|
Calcium | 1 | 2001 | 5742 | 0.000 |
Why?
|
Risk Assessment | 1 | 2009 | 23294 | 0.000 |
Why?
|